author-photo

Jennifer Curtis

Harvard University

16

Papers

400

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

2021 Nature Communications
Show All
- Source
- Cite
- Save
Citations (0)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (46)
Results of an Abbreviated Phase II Study of AKT Inhibitor MK-2206 in the Treatment of Recurrent Platinum-Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT 01283035)

2020 Gynecologic oncology reports
Show All
- Source
- Cite
- Save
Citations (5)
LBA60Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (77)
Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

2019 Gynecologic oncology reports
Show All
- Source
- Cite
- Save
Citations (4)
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

2014 Oncotarget
Show All
- Source
- Cite
- Save
Citations (39)
Abstract 1202: Patient derived xenograft model platform of high grade serous ovarian cancer supporting discovery of targeted therapies and biomarkers

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)